Paulino Tallón de Lara, MD, PhD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | University of Zurich, Zurich, CH, Cancer Biology, PhD |
| 2013 | University of Cordoba, Cordoba, ES, Human Medicine, MD |
Postgraduate Training
| 2022-2025 | Medical Oncology Fellow, Physician Scientist Track, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2019-2022 | Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York |
Licenses & Certifications
| 2022 | American Board of Internal Medicine |
| 2015 | ECFMG medical certification |
Experience & Service
Administrative Appointments/Responsibilities
European representative in the APSA (American Physician Scientist Association) Annual Meeting, European MD-PhD Association, Chicago, Illinois, 2017 - Present
Vice-president of the local committee of MEICO, IFMSA (International Federation of Students’ Medical Association), 2011 - 2012
Local Officer of Research Exchange and Local Exchange Officer, IFMSA (International Federation of Students’ Medical Association), 2009 - 2011
Other Professional Positions
Clinical Rotation, Medical Oncology, Yale University, New Haven, Connecticut, 2013 - 2013
Research and Clinical Rotations, Geneva University Hospitals, University of Geneva Switzerland, 2012 - 2013
Clinical Rotation, Neurology, Virginia Commonwealth University, Richmond, Virginia, 2012 - 2012
Research Rotation, McGill University, 2011 - 2011
Research Summer School, University of Angers, 2010 - 2010
Intramural Institutional Committee Activities
Reviewer, Residency Statistics Curriculum Working Group, Icahn School of Medicine at Mount Sinai, 2021 - 2022
Honors & Awards
| 2025 - Present | AACR Scholar-in-training award, American Association for Cancer Research |
| 2024 - Present | AACR/ASCO Methods in Clinical Cancer Research Workshop, AACR/ASCO |
| 2022 - Present | Member of the Alpha Omega Alpha National Medical Honor Society, Icahn School of Medicine at Mount Sinai Chapter |
| 2022 - Present | Best Basic Science Presentation, Mount Sinai West and Mount Sinai Morningside Research Day. Icahn School of Medicine at Mount Sinai |
| 2020 - Present | AACR Scholar-in-training award, American Association for Cancer Research |
| 2020 - Present | Best Basic Science Presentation, Mount Sinai West and Mount Sinai Morningside Research Day. Icahn School of Medicine at Mount Sinai |
| 2019 - Present | Charles Rodolphe Brupbacher Young Investigation Award, Charles Rodolphe Brupbacher Foundation. Zurich, Switzerland |
| 2018 - Present | Member of Foro Único (Honorary Alumni), University of Cordoba, Spain |
| 2018 - Present | International Travel Grant, PhD Program in Cancer Biology. University of Zurich, Switzerland |
| 2018 - Present | Golden Poster Award 17th Biennial Congress of the, Metastasis Research Society |
| 2013 - Present | Erasmus Grant, University of Geneva, Switzerland |
| 2012 - Present | MINT grant, Virginia Commonwealth University |
| 2010 - Present | French Language Grant, Spanish Ministry of Education |
| 2007 - 2013 | Matrícula de Honor, University of Cordoba |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. “El Dilema Médico”. Invited. Medical Spanish Program. Houston, Texas, US.
- 2022. Anti-metastatic response by CD8+ T cells. Conference. Mount Sinai West and Mount Sinai Morningside Research Grand Rounds. New York, New York, US.
- 2020. CD39+ PD1+ CD8+ T cells mediate metastatic dormancy in breast cancer. Conference. Mount Sinai West and Mount Sinai Morningside Research Grand Rounds. New York, New York, US.
Regional Presentations
- 2022. Inside the hematology/oncology match. Invited. New York, New York, US.
National Presentations
- 2018. T cells control dormant metastasis. Conference. Cancer Biology Student Retreat. Ascona, CH.
- 2017. The role of the immune system in the development of an early metastatic niche and metastatic dormancy. Conference. 29th Wolfsberg Meeting of the Swiss Immunology PhD students. Ermatingen, CH.
- 2016. The role of the immune system in stablishing an extravascular metastatic niche. Conference. 28th Wolfsberg Meeting of the Swiss Immunology PhD students. Ermatingen, CH.
- 2015. The role of the platelets and the immune system in spontaneous metastasis. Conference. 27th Wolfsberg Meeting of the Swiss Immunology PhD students. Ermatingen, CH.
International Presentations
- 2020. CD39+ PD1+ CD8+ T cells mediate metastatic dormancy in breast cancer. Conference. AACR Tumor Immunology and Immunotherapy, US.
- 2020. CD39+ PD1+ CD8+ T cells mediate metastatic dormancy in breast cancer. Conference. AACR Virtual Annual Meeting, US.
- 2017. European MD-PhD programs. Invited. Cordoba, ES.
- 2017. MD-PhD Programs in Europe. Invited. 13th Joint APSA/ASCI/AAP Meeting. Chicago, US.
- 2017. Histology in basic and translational immunology research. Invited. Cordoba, ES.
Formal Peers
- 2025. El Dilema Médico. Houston, Texas, US.
- 2017. European MD-PhD programs. Cordoba, ES.
- 2017. Histology in basic and translational immunology research. Cordoba, ES.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | Conquer Cancer Young Investigator Award (YIA) 2025 |
| Funding Source: | ASCO |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | The Role of the Immune System in Metastatic Dormancy |
| Funding Source: | University of Zurich |
| Role: | PI |
Selected Publications
Other Articles
- Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, Xie T, Balood M, Adewale A, Naara S, Sathishkumar HN, Islam S, McCarthy W, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Roversi K, Reza Nikpoor A, Ahmadi M, Ahmadi A, Harwood C, Leigh I, Gong D, Tallón de Lara P, Tao DL, Davidson TM, Ajami NJ, Futreal A, Rai K, Kochat V, Castillo M, Gunaratne P, Geopfert RP, Hernandez SD, Khushalani NI, Wang J, Watowich SS, Calin GA, Migden MR, Yuan M, Liu N, Ye Y, Hwang WL, Vermeer PD, D'Silva NJ, Bunimovich YL, Yaniv D, Burks JK, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo JA, Myers JN, Talbot S, Gross ND, Amit M Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature 646:462-473, 2025. PMID: 40836096.
- Pereira P, Panier J, Nater M, Herbst M, Calvanese AL, Köksal H, Castañón H, Cecconi V, Tallón de Lara P, Pascolo S, van den Broek M Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy. Cell Rep 44(3115388), 2024. PMID: 40023846.
- Liu Y, Han J, Hsu W, LaBella K, Deng P, Shang X, Tallón de Lara P, Cai L, Jiang S, DePinho RA Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model. Cancer Discov 15(162-178), 2024. PMID: 39348506.
- Fujisaki T, Sueta D, Yamamoto E, Buckley C, Sacchi de Camargo Correia G, Aronson J, Tallón de Lara P, Fujisue K, Usuku H, Matsushita K, Mehran R, Dangas GD, Tsujita K Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: A Systematic Review and Meta-Analysis. JACC CardioOncol 6(1):99-113, 2024. PMID: 38510285.
- Costa BA, Tallón de Lara P, Park W, Keane F, Harding JJ, Khalil DN Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation. Oncol Res Treat 46(5):211-215, 2023. PMID: 36882017.
- El Halabi M, Feghali J, Bahk J, Tallón de Lara P, Narasimhan B, Ho K, Sehmbhi M, Saabiye J, Huang J, Osorio G, Mathew J, Wisniyesky J, Steiger D A novel evidence-based predictor tool for hospitalization and length of stay: insights from COVID-19 patients in New York city. Intern Emerg Med 17(7):1879-1889, 2022. PMID: 35773370.
- Costa BA, Marayeyasa A, Wilkoff MH, Sacchi de Camargo Correia G, Tallón de Lara P, Rohs NC, Salonia J Primary Pulmonary NUT Carcinoma: Case Illustration and Updated Review of Literature. Clin Lung Cancer 23(4):e296-e300, 2022. PMID: 35400585.
- Tallón de Lara P, Castañón H, Sterpi M, van den Broek M Anti-metastatic response by CD8+ T cells. Trends Cancer 8(2):145-157, 2022. PMID: 34815204.
- Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdínez J, Cecconi V, Yagita H, Moyahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, van den Broek M CD39+ PD1+ CD8+ T cells mediate metastatic dormancy in breast cancer. Nat Commun 12(1):769, 2021. PMID: 33536445.
- Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Schmitt-Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel R, Britschgi C, Soldini D, Moch D, van den Broek M, Curioni-Fontecedro A Gemcitabine acts in synergy with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. Clin Cancer Res 24(24):6345-6354, 2018. PMID: 30154226.
- Arnold I, Artola-Boran M, Tallón de Lara P, Kyburz A, Taube C, Ottemann K, van den Broek M, Yousefi S, Simon HU, Müller A Eosinophils suppress Th1 responses and restrict bacterially induced gastrointestinal inflammation. J Exp Med 215(8):2055-2072, 2018. PMID: 29970473.
- Beffinger M, Tallón de Lara P, Tugues S, Vermeer M, Montagnolo Y, Ohs I, Cecconi V, Lucchiari G, Gagliardi A, Misljencevic N, Sutton J, Spörri R, Becher B, Gupta A, van den Broek M CSF1R-dependent myeloid cells are required for NK-mediated control of metastasis. JCI Insight 3(10):e97792, 2018. PMID: 29769439.
- Tallón de Lara P, Himschoot T, Frossard J-L, Negro F Does telaprevir possess a direct antidiabetic effect?. Liver Int 34(6):967-969, 2014. PMID: 24329983.
- Tallón de Lara P, Holt E, Callendar G, Cheng D, Deshpande H Management of Papillary Thyroid Cancer: An Overview for the Primary Care Physician. J Clin Outcomes Manag 21(5):233-240, 2014.
Abstracts
- Park W, Keane F, Bandlamudi C, Donoghue M, Tallón de Lara P, Harding JJ, Khalil D, McKinnell Z, Sterpi M, Cao W, El Dika IH, Balachandran VP, Soares K, Varghese AM, Yu KH, Kelsen DP, Iacobuzio-Donahue CA, Abou-Alfa GK, Solit DB, O'Reilly EM. Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade 40(16_suppl):4083, 2022. e-Pub 2022.
- Lee M, Fayad M, Mabud T, Tallón de Lara P, Espinosa Hernández A, Contreras G, Kholi M, Raymond J. Clinical Characteristics of Early Noncritical Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Single-Center Retrospective Study in New York City. Open Forum Infectious Diseases 7(Supplment 1):S287-S288, 2020. e-Pub 2020.
- Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H, Movhedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, van den Broek M. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. AACR Virtual Meeting 80(16 Supplement), 2020. e-Pub 2020.
- Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urindez J, Cecconi V, Yagita H, Movahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, van den Broek M. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. AACR Tumor Immunology and Immunotherapy 9(Supplement 2), 2020. e-Pub 2020.
- Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Opitz I, Vrugt B, Weder W, Stolzmann P, Felley-Bosco E, Stahel RA, Tischler V, Britschgi C, Soldini D, van den Broek M, Curioni-Fontecedro A. Overcoming resistance to immunotherapy in a preclinical model and mesothelioma patients. SGMO Congress 148(Supplementum 230):17S-17S, 2018. e-Pub 2018.
- Safonav A, Bandlamudi C, Tallón de Lara P, Ferraro E, Derakhshan F, Will M, Donaghue M, Selenica P, Drago J, Rosen E, dos Anjos C, Walsh E, Comen EA, Ahmed M, Acevedo B, Zehir A, Berger MF, Solit D, Norton L, Razavi P. Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance. SABCS 82((4_Supplement)).
- El Halabi M, Feghali J, Bahk J, Tallón de Lara P, Narasimhan B, Ho KS, Huang J, Osorio G, Mathew J, Wisnivesky J, Steiger D. A novel evidence-based predictor tool for hospitalization and length of stay: insights from patients with covid-19 in new york city. Chest 160(4):A553-A554.
- Ferraro E, Smith A, Safonov A, Tallón de Lara P, Bernardo C, Arenas Lahuerta EJ, Arribas J, Solit D, Reis-Filho JS, Rosen N, Norton L, Madi S, Robson ME, Dang CT, Cirigliano G, Chandarlapaty S, Razavi P. Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities. SABCS 82(4_Supplement).
Patient Reviews
CV information above last modified March 31, 2026